Directors share purchase

RNS Number:0691I
Arana Therapeutics Limited
20 November 2007


For Immediate Release                                           20 November 2007

                                                                            

                             ARANA THERAPEUTICS LTD


                           DIRECTOR'S SHARE PURCHASE


Arana Therapeutics Ltd, (LSE: AAHx ASX: AAH) ("Arana" or the "Company"), the
Australian biopharmaceutical company, formed through the merger of Peptech and
EvoGenix in August 2007. The Company uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer. The Company has received notification on 16 November 2007
that the following Director purchased ordinary fully paid shares in the capital
of the Company. Details are as follows:



Director Direct or  No. of    Date       Price per     Total          Subsequent
         Indirect   Ordinary  Purchased  Share (A$)    Consideration  beneficial
         Interest   Shares                             (A$)           holding
                    purchased     
                                   
Greg     Direct     50,000     15         1.185        59,250         300,000
Bundy                          November
                               2007


For further information, please contact:

Arana Therapeutics Ltd
Dr John Chiplin, Chief Executive Officer              +61 (0)2 9870 8788
Niall Henderson, Chief Financial Officer              +61 (0)2 9870 8788

Buchanan Communications
Lisa Baderoon (lisab@buchanan.uk.com)                 +44 (0)20 7466 5000
Rebecca Skye Dietrich / Catherine Breen

Nomura Code Securities
Charles Walker                                        +44 (0)20 7776 1206






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSOKKKQFBDKNDB

Arana Therap. (LSE:AAHX)
過去株価チャート
から 5 2024 まで 6 2024